Analysts forecast that OptiNose Inc (NASDAQ:OPTN) will post earnings of ($0.84) per share for the current quarter, according to Zacks. Two analysts have made estimates for OptiNose’s earnings, with estimates ranging from ($0.88) to ($0.79). OptiNose posted earnings per share of ($0.64) during the same quarter last year, which would indicate a negative year over year growth rate of 31.3%. The company is expected to report its next quarterly earnings results on Tuesday, March 12th.
According to Zacks, analysts expect that OptiNose will report full year earnings of ($2.93) per share for the current fiscal year, with EPS estimates ranging from ($3.04) to ($2.76). For the next fiscal year, analysts expect that the firm will post earnings of ($2.75) per share, with EPS estimates ranging from ($3.19) to ($2.29). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover OptiNose.
OptiNose (NASDAQ:OPTN) last released its earnings results on Tuesday, November 13th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.11. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.57 million.
OPTN has been the topic of several analyst reports. Cantor Fitzgerald set a $30.00 target price on OptiNose and gave the stock a “buy” rating in a report on Tuesday, August 14th. Piper Jaffray Companies set a $30.00 target price on OptiNose and gave the stock a “buy” rating in a report on Tuesday, August 14th. Zacks Investment Research lowered OptiNose from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Finally, BMO Capital Markets reduced their target price on OptiNose from $30.00 to $28.00 and set an “outperform” rating on the stock in a report on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. OptiNose currently has a consensus rating of “Buy” and an average target price of $28.75.
OPTN opened at $8.08 on Wednesday. OptiNose has a 52-week low of $7.33 and a 52-week high of $30.00. The company has a debt-to-equity ratio of 0.51, a quick ratio of 10.13 and a current ratio of 10.44.
A number of large investors have recently added to or reduced their stakes in OPTN. Massachusetts Financial Services Co. MA boosted its stake in OptiNose by 1.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 703,962 shares of the company’s stock valued at $19,697,000 after buying an additional 9,763 shares in the last quarter. State of New Jersey Common Pension Fund D acquired a new stake in OptiNose in the second quarter valued at about $2,531,000. Wells Fargo & Company MN boosted its stake in OptiNose by 60.0% in the second quarter. Wells Fargo & Company MN now owns 454,160 shares of the company’s stock valued at $12,708,000 after buying an additional 170,382 shares in the last quarter. Rice Hall James & Associates LLC acquired a new stake in OptiNose in the second quarter valued at about $9,047,000. Finally, Kornitzer Capital Management Inc. KS boosted its stake in OptiNose by 11.0% in the second quarter. Kornitzer Capital Management Inc. KS now owns 352,980 shares of the company’s stock valued at $9,876,000 after buying an additional 35,000 shares in the last quarter. 50.30% of the stock is currently owned by institutional investors and hedge funds.
OptiNose Company Profile
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.
Recommended Story: Cost of equity and a company’s balance sheet
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OptiNose Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptiNose and related companies with MarketBeat.com's FREE daily email newsletter.